<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755569</url>
  </required_header>
  <id_info>
    <org_study_id>Impulse Dynamics</org_study_id>
    <nct_id>NCT04755569</nct_id>
  </id_info>
  <brief_title>Optimizer System With ODOCOR II CCM™ Leads</brief_title>
  <official_title>Clinical Investigation of the ODOCOR II CCM™ Leads in Patients With Optimizer System Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the ODOCOR II CCM lead study is to evaluate the safety and useability of the&#xD;
      ODOCOR II intra-cardiac lead specifically intended to deliver CCM as an accessory lead to the&#xD;
      Optimizer IPG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design A prospective, multi-center, single arm open label study, 12-month study of 400 ODOCOR&#xD;
      II CCM™ leads in 200 subjects .&#xD;
&#xD;
      Method Subjects shall be enrolled that have been diagnosed with NYHA Class III-IV heart&#xD;
      failure and left ventricular ejection fraction (25-45% inclusive). Eligible subjects will&#xD;
      receive the Optimizer IPG device implant with 2 ODOCOR II CCM leads. Subjects will return for&#xD;
      follow-up visits at 2-weeks, 6 months and 12 months following the device implant.&#xD;
&#xD;
      Endpoints Primary Safety endpoint&#xD;
&#xD;
      The primary safety endpoint is the incidence of lead-related complication free rate at 12&#xD;
      months post-index implantation procedure compared to the incidence previously described in&#xD;
      the literature for pacing therapy leads.&#xD;
&#xD;
      Secondary Safety endpoint&#xD;
&#xD;
      The secondary safety endpoint is an assessment of the lead-related &quot;observations&quot; occurring&#xD;
      during the 12-month study.&#xD;
&#xD;
      Primary Efficacy endpoint The total amount of CCM delivered to the cardiac tissue of the&#xD;
      right ventricle (measured by CCM percentage) will be measured over a period of 12 months.&#xD;
&#xD;
      Secondary Efficacy endpoint Change in QOL, as measured by the Minnesota Living with Heart&#xD;
      Failure Questionnaire (MLWHFQ), from baseline to 12 months following index implantation&#xD;
      procedure.&#xD;
&#xD;
      Additional Endpoints Handling characteristics of the lead will be evaluated by the implanting&#xD;
      physician. Ease of insertion, lead visibility on x-ray, and the ability to visualize the&#xD;
      helix deployment will be assessed via a questionnaire administered at the completion of an&#xD;
      implant procedure.&#xD;
&#xD;
      Patients, sites Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible&#xD;
      subjects from up to 40 sites in Europe.&#xD;
&#xD;
      Duration The total investigation is expected to last approximately 3 years , including&#xD;
      enrollment and follow-up periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Primary Safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint is the incidence of lead-related complication free rate at 12 months post-index implantation procedure compared to the incidence previously described in the literature for pacing therapy leads.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy endpoint</measure>
    <time_frame>12 month</time_frame>
    <description>The total amount of CCM delivered to the cardiac tissue of the right ventricle (measured by CCM percentage) will be measured over a period of 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety endpoint</measure>
    <time_frame>12 month</time_frame>
    <description>The secondary safety endpoint is an assessment of the lead-related &quot;observations&quot; occurring during the 12-month study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy endpoint</measure>
    <time_frame>12 month</time_frame>
    <description>Change in QOL, as measured by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ), from baseline to 12 months following index implantation procedure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Additional Endpoints</measure>
    <time_frame>at implant</time_frame>
    <description>Handling characteristics of the lead will be evaluated by the implanting physician. Ease of insertion, lead visibility on x-ray, and the ability to visualize the helix deployment will be assessed via a questionnaire administered at the completion of an implant procedure.</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ODOCOR II CCM LEADS</intervention_name>
    <description>ODOCOR II CCM LEADS Implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The total investigation is expected to last approximately 3 years , including enrollment&#xD;
        and follow-up periods.&#xD;
&#xD;
        Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible subjects from up&#xD;
        to 40 sites in Europe&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient signed and dated informed consent form&#xD;
&#xD;
          2. Male or non-pregnant female, aged 18 or older&#xD;
&#xD;
          3. Left ventricular ejection fraction of 25-45% (inclusive)&#xD;
&#xD;
          4. Diagnosed with NYHA Class III or IV heart failure&#xD;
&#xD;
          5. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          6. Medically stable and with no significant mental illness in the judgement of the&#xD;
             principal investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infiltrative or inflammatory cardiomyopathy (e.g. amyloid, hemochromatosis,&#xD;
             myocarditis, hypertrophic cardiomyopathy, Fabry's disease, cardiac tumor)&#xD;
&#xD;
          2. Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair&#xD;
             or clip within 3 months of the baseline testing visit.&#xD;
&#xD;
          3. IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days&#xD;
             before the baseline testing visit, including continuous IV inotrope therapy&#xD;
&#xD;
          4. Myocardial infarction within 3 months of the baseline testing visit.&#xD;
&#xD;
          5. Undergone a CABG procedure within 3 months90 days or a PTCA procedure within 30 days&#xD;
             of the baseline testing visit.&#xD;
&#xD;
          6. Undergone a cardiac ablation procedure within 90 days prior to consent.&#xD;
&#xD;
          7. Prior heart transplant or ventricular assist device&#xD;
&#xD;
          8. Mechanical tricuspid valve&#xD;
&#xD;
          9. Receiving cardiac resynchronization therapy (CRT) or indicated for Class I CRT&#xD;
             implantation according to the ACCF/AHA/HRS guidelines for device-based therapy&#xD;
&#xD;
         10. Currently on dialysis&#xD;
&#xD;
         11. Currently undergoing active chemotherapeutic and/or radiation treatment for cancer&#xD;
&#xD;
         12. Participating in another cardiac investigational device study at the same time&#xD;
&#xD;
         13. Patient is in a vulnerable population (such as significant mental disability,&#xD;
             prisoner) that in the judgement of the PI impedes ability to provide informed content.&#xD;
&#xD;
         14. Expected lifespan of less than 12 months from time the baseline testing visit.&#xD;
&#xD;
         15. Resting heart rate &gt;110 bpm at the time of the baseline testing visit&#xD;
&#xD;
         16. Current drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements&#xD;
&#xD;
         17. Subjects currently admitted to the hospital with a primary diagnosis of heart failure&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Gaspar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Stagg</last_name>
    <phone>+01 845 558 9391</phone>
    <email>angelas@impulsedynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik am Plattenwald</name>
      <address>
        <city>Heilbronn</city>
        <state>Baden Wuerttemberg</state>
        <zip>74177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Dengler, Prof. Dr.</last_name>
      <phone>0049 071362854001</phone>
      <email>thomas.dengler@slk-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Christina Lindner</last_name>
      <phone>0049071362854350</phone>
      <email>christiner.lindner@slk-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Dengler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anna Krankenhaus</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <state>Bavaria</state>
        <zip>92237</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flamur Kryezi, Dr.</last_name>
      <phone>+49 170 1039794</phone>
      <email>f.kryezi@kh-as.de</email>
    </contact>
    <investigator>
      <last_name>Flamur Kryezi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital Wiesbaden GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Ehrlich, Prof. Dr.</last_name>
      <email>jehrlich@joho.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Stade</name>
      <address>
        <city>Stade</city>
        <state>Lower Saxony</state>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Marx, Dr.</last_name>
      <phone>0049 4141972956</phone>
      <email>oliver.marx@elbeklinikum.de</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Beyer</last_name>
      <phone>00494141972841</phone>
      <email>vanessa.beyer@elbeklinikum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver Marx, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Marie-Hilf Stadtlohn</name>
      <address>
        <city>Stadtlohn</city>
        <state>North Rhine Westphalia</state>
        <zip>48703</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Cuneo, Dr.</last_name>
      <phone>0049 25639126961</phone>
      <email>a.cuneo@kmh-stadtlohn.de</email>
    </contact>
    <contact_backup>
      <last_name>Britta Fitz</last_name>
      <phone>0049 25639126373</phone>
      <email>b.fitz@kmh-stadtlohn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Cuneo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt Bochum-Mitte</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine-Westphalia</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus W. Prull, Dr.</last_name>
      <phone>0049234 5172351</phone>
      <email>m.prull@augusta-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Traebing</last_name>
      <phone>0049234 5172235</phone>
      <email>v.traebing@augusta-bochum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dave Wenzel</last_name>
      <email>dave.wenzel@med.ovgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Schaefer</last_name>
      <email>kerstin.schaefer@med.ovgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Conrad Genz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Wenzel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gaspar, Dr.</last_name>
      <phone>0049 351 45025412</phone>
      <email>thomas.gaspar@herzzentrum-dresden.com</email>
    </contact>
    <contact_backup>
      <last_name>Anastasia Hankel</last_name>
      <phone>0049 351 45025412</phone>
      <email>anastasia.hankel@herzzentrum-dresden.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Gaspar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Koepenick</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Spencker, Dr.</last_name>
      <phone>0049 3030353318</phone>
      <email>s.spencker@drk-kliniken-berlin.de</email>
    </contact>
    <contact_backup>
      <last_name>Silke Helms</last_name>
      <phone>0049 3030353777</phone>
      <email>s.helms@drk-kliniken-berlin.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sebastian Spencker, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Berlin Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Blaschke, Dr.</last_name>
      <phone>+49 30 450 653635</phone>
      <email>florian.blaschke@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Svenja Broschag</last_name>
      <phone>+49 30 450 653762</phone>
      <email>svenja.broschag@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Florian Blaschke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phillip Lacour, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten W. Israel</last_name>
      <phone>+49 52177277525</phone>
      <email>carsten.israel@evkb.de</email>
    </contact>
    <contact_backup>
      <last_name>Christina Schaefer</last_name>
      <phone>+49 521 772 77640</phone>
    </contact_backup>
    <investigator>
      <last_name>Carsten W. Israel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Feldmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH Krankenhaus Waltershausen-Friedrichroda</name>
      <address>
        <city>Friedrichroda</city>
        <zip>99894</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schuemmelfeder</last_name>
      <phone>+49 3623 3500</phone>
      <email>joachim.schuemmelfeder@kwf.srh.de</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Litzkow</last_name>
      <email>andrea.Litzkow@srh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joachim Schuemmelfeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45886</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Kloppe, PD Dr. med.</last_name>
      <phone>+49 172 28 26 868</phone>
      <email>a.kloppe@marienhospital.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Kaiser, Dr.</last_name>
      <phone>0049 4018188555406</phone>
      <email>k.lukas@asklepios.com</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Kalkowski</last_name>
      <phone>0049 401818852070</phone>
      <email>c.kalkowski@asklepios.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lukas Kaiser, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schoen Klinik Hamburg Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hennersdorf</last_name>
      <phone>+49 40 20921201</phone>
      <email>fhennersdorf@schoen-klinik.de</email>
    </contact>
    <investigator>
      <last_name>Frank Hennersdorf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Halboos</last_name>
      <email>a.halboos@evk-herne.de</email>
    </contact>
    <investigator>
      <last_name>Ali Halboos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum UMM</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Kuschyk, Prof. Dr.</last_name>
      <phone>+49 1713453211</phone>
      <email>juergen.kuschyk@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Brigitte Kircher</last_name>
      <phone>+49 6213831993</phone>
      <email>brigitte.kircher@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen Kuschyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Rudic</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken Marienhospital Osnabrück GmbH</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wichter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Dei Colli-Monaldi</name>
      <address>
        <city>Naples</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio D'Onofrio, Dr.</last_name>
      <email>donofrioant1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio D'Onofrio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Sacra Famiglia&quot; - Fatebenefratelli dell'</name>
      <address>
        <city>Erba</city>
        <state>Lombardo Veneta</state>
        <zip>22036</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sagone, Dr.</last_name>
      <email>asagone@fatebenefratelli.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale C. e G. &quot;Mazzoni&quot;</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Procolo Marchese, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Procolo Marchese, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Carugo, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Patti</last_name>
      <email>giuseppe.patti@maggioreosp.novara.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Patti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele Dell'Era</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Marconetto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Sant'Andrea</name>
      <address>
        <city>Vercelli</city>
        <zip>13100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Matta</last_name>
      <email>m.matta26@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mario Matta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza - Azienda UlSS 8 Berica</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Rosillo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Rosillo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitario Torrecardenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Aceituno Cubero, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Aceituno Cubero, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Lopez, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Fontenla Cerezuela, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Adolfo Fontenla Cerezuela, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Fernandez Lozano, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Fernandez Lozano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico U. de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Garcia Seara, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Javier Garcia Seara, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

